Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Multiple Myeloma 2Breast Neoplasms 2Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Advanced Breast Cancer 1

Interventions

Trastuzumab 628Paclitaxel 577Cyclophosphamide 555Docetaxel 485Capecitabine 402Letrozole 376Fulvestrant 327Doxorubicin 294Carboplatin 279Tamoxifen 275Anastrozole 243exemestane 228Radiotherapy 218Epirubicin 211Bevacizumab 196palbociclib 189pertuzumab 186Vinorelbine 167Lapatinib 167Gemcitabine 166pembrolizumab 162Surveys and Questionnaires 139Exercise 136Magnetic Resonance Spectroscopy 123Fluorouracil 119Blood Specimen Collection 118eribulin 117Albumin-Bound Paclitaxel 117Drug Therapy 111130-nm albumin-bound paclitaxel 111

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Breast Neoplasms × balixafortide × Clear all
NCT03786094 2023-11-01

FORTRESS

Spexis AG

Phase 3 Terminated
432 enrolled 13 charts
Breast

Breast Neoplasms

NCT01837095 2018-09-14

Dose Escalation of POL6326 in Combination With Eribulin in Patients With Metastatic Breast Cancer

Polyphor Ltd.

Phase 1 Completed
54 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡